Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.

Lars L F G ValkeLaura H BukkemsWideke BartelingBritta A P Laros-van GorkomNicole M A BlijlevensRon A A MathôtWaander L van HeerdeSaskia E M Schols

Published in: Journal of thrombosis and haemostasis : JTH (2020)

HA patients showed clear differences in baseline TG and PG despite having comparable FVIII activity levels. These results reveal a discrepancy between FVIII activity level and TG, in which the latter may be a better parameter to monitor individualized treatment in HA patients.

Keyphrases

end stage renal disease
replacement therapy
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported